Biogen (BIIB) Return on Capital Employed (2009 - 2026)

Biogen (BIIB) has reported Return on Capital Employed for 18 consecutive years, with 3.07% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Capital Employed fell 24.0% year-over-year to 3.07%; the TTM figure through Mar 2026 stood at 3.07% (down 24.0% YoY), while the FY2025 annual figure was 3.34%, down 149.0% from the prior year.
• Return on Capital Employed came in at 3.07% for Q1 2026 at Biogen, up from 3.26% in the prior quarter.
• The five-year high for Return on Capital Employed was 14.37% in Q2 2022, with the low at 3.26% in Q4 2025.
• Average Return on Capital Employed over 5 years is 2.43%, with a median of 2.17% recorded in 2023.
• Across the five-year window, Return on Capital Employed soared 406 bps in 2022 and plunged 1602 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 12.77% in 2022, then slumped by 125 bps to 3.25% in 2023, then soared by 45 bps to 1.79% in 2024, then slumped by 83 bps to 3.26% in 2025, then gained by 6 bps to 3.07% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 3.07%, 3.26%, and 2.31% for Q1 2026, Q4 2025, and Q3 2025 respectively.